From: Radiosensitization in prostate cancer: mechanisms and targets
Trial description | Sponsor | Status |
---|---|---|
Sunitinib with hormonal ablation in patients with localized prostate cancer | MD Anderson Cancer Center | Ongoing, not recruiting |
SU5416 with hormonal ablation in patients with localized prostate cancer | University of Chicago | Unknown |
Everolimus with hormonal ablation in patients with high risk localized prostate cancer | University of Michigan | Not yet open |
TAK-700 with hormonal ablation in patients with high risk localized prostate cancer | Radiation Therapy Oncology Group | Recruiting |
Everolimus with hormonal ablation in patients with high risk locally advanced prostate cancer | Centre Val d’Aurelle – Paul Lamarque | Recruiting |
Bevacizumab with hormonal ablation in patients with high risk localized prostate cancer | Benaroya Research Institute | Completed |
Everolimus for salvage treatment of biochemical recurrence after prostatectomy | Abramson Cancer Center of the University of Pennsylvania | Recruiting |
IL-12 gene therapy | Baylor College of Medicine | Completed |
ProstAtakâ„¢ in patients with localized prostate cancer | Advantagene, Inc. | Recruiting |
Isoflavones in patients with localized prostate cancer | Barbara Ann Karmanos Cancer Institute | Completed |
Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer | University of Alabama | Completed |
Selenomethionine in patients with localized prostate cancer | Roswell Park Cancer Center | Withdrawn |
R-Flubiprofen in patients with high risk localized prostate cancer | Myrexis Inc. | Unknown |
Panobinostat in patients with localized prostate cancer | Novartis Pharmaceuticals | Completed |